Snapshot from Jul 07, 2026 at 01:18 UTC. For live data and tracking: View Live
Entities / IBM System/4 Pi
Other

IBM System/4 Pi

Tracked across 1 events · 6 articles · First seen Jun 24, 2026 · Last active Jun 24, 2026

Sentiment
70
Attention
6
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
Events (1)
6 70
Tech
AL-S Pharma AP-101 Phase 2 Success
Impact: IBM System/4 Pi is the investigational human-derived antibody developed by ALS Pharma that showed positive results in its Phase 2 clinical trial for ALS, targeting misfolded SOD1 to slow disease progression and prolong survival.
Jun 24, 2026 · 6 articles
Key Actions (3)
40 United States — Food and Drug Administration granted Orphan Drug IBM System/4 PiAL-S Pharma AP-101 Phase 2 Success
40 European Union — European Medicines Agency granted Orphan Drug IBM System/4 PiAL-S Pharma AP-101 Phase 2 Success
40 Switzerland — Swissmedic granted Orphan Drug IBM System/4 PiAL-S Pharma AP-101 Phase 2 Success
ERGEN INTELLIGENCE
Track IBM System/4 Pi live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.